The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is currently being investigated as a potential therapeutic target in several ...

Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals ...

Currently, PET scanner validation phantoms, methods, and acceptance criteria for clinical trials are not standardized. This ...

Whole-body CD8+ T-cell PET imaging can detect spatial and temporal localization of CD8+ T cells. To obtain insight into early CD8+ T-cell response to immunotherapy in patients with melanoma, a highly ...

Fibroblast activation protein (FAP)–targeted imaging has emerged as a promising diagnostic tool for various oncologic and nononcologic conditions. However, the increasing employment of FAP-targeted ...

The study of the human phenome is essential for understanding the complexities of wellness and disease and their transitions, with molecular imaging being a vital tool in this exploration. Molecular ...

223Ra-dichloride (223Ra) is an approved therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC) who have symptomatic bone metastases. After an initial course of 6 ...

Nuclear medicine has evolved from a diagnostic-oriented speciality toward theranostics. Radionuclide therapy has become a booming business with newer radiopharmaceuticals and indications. Although the ...

Heat shock protein 90 (Hsp90) is essential for maintaining cellular proteostasis and may play an important role in the development of neurodegenerative proteinopathies. Therefore, we aimed to develop ...

Prostate-specific membrane antigen (PSMA)–targeted radiopharmaceutical therapy has demonstrated promising potential for treating metastatic castration-resistant prostate cancer. Recently, ...

AB001, a prostate-specific membrane antigen (PSMA)–targeted small molecule labeled with the in vivo–generating α-emitter 212Pb, was investigated in a phase 0 trial in patients with metastatic ...

Pilot Study of Nectin-4–Targeted PET Imaging Agent 68 Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human ...